Alnylam Pharmaceuticals, Axsome, Summit Stocks

This is a news story, published by Yahoo Finance, that relates primarily to Alnylam Pharmaceuticals news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Summit Therapeutics stock

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biotech stocks news, healthcare stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Alnylam Pharmaceuticals

The Motley Fool

•

Health

3 High-Flying Stocks That Could Soar Even More

Summary

Nutrition label

77% Informative

Alnylam Pharmaceuticals has had a lot of excitement this year , with more good news potentially on the way.

Summit Therapeutics could keep its momentum going with positive clinical results for cancer drug ivonescimab.

The Fool's contributors think they've found high-flying biotech stocks that could soar even more.

Summit Therapeutics stock has soared 440% in the past 12 months .

The company doesn't even have an approved product yet, but it's possible that it could still go higher.

Investors should tread carefully because there is considerable risk with the stock, as the business isn't generating revenue and there's not much else to fall back on.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful